Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty

被引：16

作者：

Hilal, Talal ^{[1
]}

Betcher, Jeffrey A. ^{[2
]}

Leis, Jose F. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol & Med Oncol, 5881 E Mayo Blvd, Phoenix, AZ 85054 USA

[2] Mayo Clin, Dept Pharm, Phoenix, AZ USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2018年 / 13卷 / 04期

关键词：

CLL; Ibrutinib; Idelalisib; Venetoclax; Drug costs; Pharmacoeconomics; financial toxicity; OPEN-LABEL; INITIAL THERAPY; CANCER DRUGS; IBRUTINIB; RITUXIMAB; COST; IDELALISIB; CYCLOPHOSPHAMIDE; FLUDARABINE; MULTICENTER;

D O I：

10.1007/s11899-018-0461-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.

引用

页码：237 / 243

页数：7

共 41 条

[1]

[Anonymous], JAMA ONCOL

[2]

[Anonymous], DRUG BENEFIT

[3]

[Anonymous], DRUGS FDA FDA APPR D

[4]

[Anonymous], 2015, BLOOD

[5] Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs [J].

Bach, Peter B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06) :626-633

[6] Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications [J].

Betcher, Jeffrey ;

Dow, Elizabeth ;

Khera, Nandita .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (04) :288-294

[7] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

Byrd, John C. ;

Coutre, Steven E. ;

Benson, Don M. ;

Flinn, Ian W. ;

Wagner-Johnston, Nina D. ;

Spurgeon, Stephen E. ;

Kahl, Brad S. ;

Bello, Celeste ;

Webb, Heather K. ;

Johnson, Dave M. ;

Peterman, Sissy ;

Li, Daniel ;

Jahn, Thomas M. ;

Lannutti, Brian J. ;

Ulrich, Roger G. ;

Yu, Albert S. ;

Miller, Langdon L. ;

Furman, Richard R. .

BLOOD, 2014, 123 (22) :3390-3397

[8] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[9] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[10] Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States [J].

Chen, Qiushi ;

Jain, Nitin ;

Ayer, Turgay ;

Wierda, William G. ;

Flowers, Christopher R. ;

O'Brien, Susan M. ;

Keating, Michael J. ;

Kantarjian, Hagop M. ;

Chhatwal, Jagpreet .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :166-+

← 1 2 3 4 5 →